Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners

Biophytis announces major progress in preparing its OBA Phase 2 trial of BIO101 in muscle wasting associated with obesity. The Company via its subsidiary in Brazil has secured funding support from EMBRAPII (Empresa Brasileira de Pesquisa e Inovação Industrial) and entered into agreements with two of the most respected obesity medical research and clinical centers in Brazil: FARMAVAX-UFMG (Inovação de Fármacos e Vacinas, Federal University of Minas Gerais) and FMRP-USP (Faculty of Medicine of Ribeirão Preto, University of São Paulo).

Strengthening the OBA Phase 2 Program in Brazil

With 122 of the 164 patients planned to be recruited in Brazil, the region is central to the success of the OBA trial. The agreements with FARMAVAX-UFMG and FMRP-USP provide Biophytis with:

  • Access to leading clinical expertise in obesity and metabolic disorders,
  • A large and diverse patient population for efficient recruitment,
  • Established infrastructure for high-quality clinical research aligned

These partnerships ensure that Brazil will play a pivotal role in the generation of robust clinical data for BIO101 in this new high-prevalence indication.

Non-Dilutive Funding Support Through EMBRAPII

Biophytis also announced that it has secured support from EMBRAPII, a government-backed innovation agency in Brazil dedicated to fostering industrial R&D collaboration and accelerating clinical innovation. This partnership will provide non-dilutive funding for the OBA Phase 2 trial, reducing cash requirements for the Company while validating the strategic importance of the program at a national level.

“This recognition from EMBRAPII and our agreements with FARMAVAX-UFMG and FMRP-USP represent a very strong validation of our program in Brazil” said Stanislas Veillet, President and CEO of Biophytis. “It reflects both the medical urgency of addressing obesity-linked muscle wasting and the confidence that leading academic institutions have in the potential of BIO101. For Biophytis, this allows the Phase 2 OBA trial to move forward and provides a solid foundation for rapid recruitment and data generation.”

Strategic and Investor Impact

These developments represent significant value creation milestones for Biophytis:

  • Financial de-risking through non-dilutive EMBRAPII support,
  • Operational acceleration via leading Brazilian recruitment sites,
  • Reinforced credibility both scientifically and strategically, given the involvement of top-tier medical institutions.

For investors, this milestone strengthens the likelihood of timely trial initiation and execution, reduces capital intensity, and validates the importance of BIO101 in addressing an emerging multi-billion-euro global therapeutic segment.

Next Steps

Biophytis remains focused on:

  • Finalizing additional site agreements in Europe to complete its site network,
  • Securing final regulatory approvals from ANVISA and EMA,
  • Initiating patient enrolment in the OBA Phase 2 trial across both regions.

With strong clinical partners and co-funding mechanisms now in place, the Company to advance towards first patient dosing in the near term.

Fullscreen Mode